Sensitive and Reliable Results

Concentrations of ctDNA vary among tumor types and among individuals. This variability in ctDNA concentration creates the need for a highly sensitive technology to detect genomic mutations at lower concentrations. The Follow It assay detects mutations down to 0.1% variant allele frequency*.

Follow It detects common, clinically relevant genomic alterations in solid tumor samples, including single-base substitutions (SNVs), small deletions, and insertions (up to 24bp). It evaluates the mutation status of tumor DNA at 337 hotspots and 26 exons in 38 known cancer-associated genes simultaneously.

Follow It targets genes for non-small cell lung cancer, melanoma, colorectal cancer, GIST, basal cell, breast cancer, endometrial, and other solid tumor cancers.

GenePosition
AKT1E17
ALK T1151, L1152, C1156, F1174, L1196, L1198, G1202, D1203, S1206, G1269, R1275, Y1278
ARL702, V716, S741, W742, Q784, H875, F877, T878, M896
BRAFQ201, G464, G466, F468, G469, Y472, D594, F595, G596, L597, V600, K601, part of Exon15 (V600-M620), G606
CCNEAmplification
CTNNB1D32, S33, G34, I35, H36, S37, T41, S45
DDR2L239, I638, S768
DICER1D1705-D1709, G1809, D1810-E1813
EGFR R108, A289, S492, P596, G598, Exon18, Exon19, Exon20, Exon21, & Amplification
ERBB2G309, S310, K753, L755, I767, D769, Exon20, & Amplification
ESR1K303, E380, S463, V534, P535, L536, Y537, D538
FGFR1N546, K656 + Amplification
FGFR2 S252, P253, W290, A315, S372, Y375, C382, N549, K659, E731, E777, & Amplification
FGFR3R248, S249, G370, S371, Y373, G380, A391, K650
FOXL2C134
GNA11Q209
GNAQQ209
GNASR201
HRASG12, G13, Q61
IDH1R132
IDH2R140, R172
KITS476, Y553, W557,, V559, V560, L576, K642, V654, T670, D816, D820, N822, Y823, A829, Exon9, Exon11, Exon13, & Amplification
KRASK5, A11, G12, G13, L19, Q22, A59, G60, Q61, K117, A146, & Amplification
MAP2K1(MEK1)F53, Q56, K57, K59, V60, D67, I103, I111, C121, N122, P124, P387
MAP2K2(MEK2)F57, Q60, K61, L119, H123, G132
MET T1010, V1112, H1112, G1181, L1213, D1246, Y1248, Y1253, Exon13, Exon14, Exon14 (-50 to+25), Exon18, Amplification
NRASG12, G13, A59, G60, Q61, K117, A146
NTRK1F589, G595, G667
NTRK3G623, G696
PDGFRAR560-E571, P577, N659, L839-Y849, D842
PIK3CAR88, C90, R93, P104, G106, N107, R108, K111, R115, N345, R357, G364, E365, Exon6 [start to P377], C420, E453, P539, E542, E545, Q546, D549, E970, E978, M1043, N1044, A1046, H1047, G1049, & Amplification
POLEExons 9-14 (P286R, M295R, S297F, F367S, D368Y, V411L, L424I, M444K, A456P, S459F)
PTCH1W844, G1093
PTENA126, G129, R130, R173, R233, K254-K267
RETG533, K603, C609, C611, C618, C620, C630, D631, C634, G691, E768, L790, Y791, V804, Y806, A883, R886, S904, M918, A919, Exon10, Exon 13, Exon15
ROS1S1986, G2032, L2026
STK11Q37, P281
TP53Exon4, Exon5, Exon6, Exon7, Exon8, Exon9
MSI21 Loci
Breast Cancer
Biomarkers detected by Plasma (Follow It®)Available FDA Approved TherapyNCCN BiomarkerAMP/ASCO/CAP Tier*Resistance
AKT1 E17KNoNoIBNo
ERBB2 amplificationYesYesIANo
ERBB2 oncogenic mutationsNoNoIBNo
ESR1 oncogenic mutationsNoNoIBNo
FGFR1 amplificationNoNoIICNo
PIK3CA oncogenic mutationsYesYesIANo
MSI-HYesYesIANo
Colorectal Cancer
Biomarkers detected by Plasma (Follow It®)Available FDA Approved TherapyNCCN BiomarkerAMP/ASCO/CAP Tier*Resistance
BRAF V600EYesYesIANo
ERBB2 AmplificationYesYesIA/IBYes
KRAS wild typeYesYesIANo
KRAS and NRAS wild-typeYesYesIANo
KRAS and NRAS oncogenic mutationsYesYesIAYes
MSIYesYesIANo
Endometrial Cancer (Metastatic Cases)
Biomarkers detected by Plasma (Follow It®)Available FDA Approved TherapyNCCN BiomarkerAMP/ASCO/CAP Tier*Resistance
AKT1 E17KNoNoIBNo
MSI/MMRdYesYesIANo
POLENoYesNoNo
Gastric
Biomarkers detected by Plasma (Follow It®)Available FDA Approved TherapyNCCN BiomarkerAMP/ASCO/CAP Tier*Resistance
ERBB2 amplificationYesYesIANo
MSIYesYesIANo
GIST
Biomarkers detected by Plasma (Follow It®)Available FDA Approved TherapyNCCN BiomarkerAMP/ASCO/CAP Tier*Resistance
KIT oncogenic mutationsYesYesIA/IIDNo
KIT A829, D816, D820, N822, T670, V654, Y823YesYesIIDYes
KIT V654YesYesIIDYes
PDGFRA oncogenic mutationsYesYesIANo
PDGFRA D842YesYesIAYes
NSCLC
Biomarkers detected by Plasma (Follow It®)Available FDA Approved TherapyNCCN BiomarkerAMP/ASCO/CAP Tier*Resistance
ALK oncogenic mutationsYesNoIA/IIDYes
BRAF V600EYesYesIANo
EGFR G719 (exon 18), exon 19 deletions, S768I (exon 20), L858R, L861Q (exon21)YesYesIANo
EGFR exon 19 deletions, L858R (exon 21)YesYesIANo
EGFR exon 20 insertion, T790M (exon 20)YesYesIAYes
EGFR T790M (exon 20), L858R (exon 21)YesYesIANo
EGFR C797, L718, L792, G796YesYesIIDYes
EGFR exon 20 insertionYesYesIANo
EGFR exon 18 indelNoYesIBNo
EGFR exon 19 insertionNoYesIBNo
EGFR exon 19 & 20 insertion, L747NoYesIIDNo
ERBB2 oncogenic mutationsYesYesIANo
KRAS G12CYesYesIANo
MAP2K1 oncogenic mutationsNoNoIBNo
MET exon 14 skippingYesYesIANo
MET amplificationYesYesIA/IIDYes
Melanoma
Biomarkers detected by Plasma (Follow It®)Available FDA Approved TherapyNCCN BiomarkerAMP/ASCO/CAP Tier*Resistance
BRAF V600YesYesIANo
BRAF V600EYesYesIANo
BRAF V600KYesYesIANo
BRAF L597, V601NoYesIBNo
KIT oncogenic mutationsYesYesIANo
MAP2K1 oncogenic mutationsNoNoIBNo
NRAS oncogenic mutationsNoYesIB/IIDNo
Urothelial Cancer
Biomarkers detected by Plasma (Follow It®)Available FDA Approved TherapyNCCN BiomarkerAMP/ASCO/CAP Tier*Resistance
FGFR3 R248C, S249C, G370C, Y373CYesYesIANo
FGFR3 S371C, G380R, K650NoYesIBNo
HRAS oncogenic mutuationsNoNoIBNo
All Solid Tumors
Biomarkers detected by Plasma (Follow It®)Available FDA Approved TherapyNCCN BiomarkerAMP/ASCO/CAP Tier*Resistance
BRAF G464, G469, L597, K601NoNoIIDNo
FGFR1, FGFR2, FGFR3 oncogenic mutationsNoNoIIDNo
KRAS oncogenic mutationsNoNoIIDNo
Microsatellite Instability-High (MSI-H)YesYesIANo
NTRK1 and NTRK3 mutationsYesNoIAYes
NTRK1 G595RYesNoIIDYes
PTEN oncogenic mutationsNoNoIIDNo
Genes38
Hotspots337
Exons26
Turnaround Time3-5 days
Mutation typesSNVs, deletions and insertions (up to 24bp), CNVs
Sample TypeBlood
Sample Requirement2 x 10 mL of blood in Streck tubes

Benefits

Relevant Results

Target mutations and other genomic aberrations commonly associated with prevalent solid tumors.

End to End Solution

Single Integrated assay, analysis, and reporting platform streamlines assay and results reporting workflow.

Comprehensive Reports

Review detailed interpretations, current treatment options, and available clinical trials.

Cost-Effective

Targeted amplicon-based technology provides an economical alternative to single-gene testing or hybrid capture NGS assays.

Minimally Invasive

A minimally invasive option for clinical research, Follow It can also be used to observe cancer progression or detection of treatment resistance.

Accreditation

All Canexia Health assays and software are developed in our CLIA, CAP, CDPH and DAP accredited laboratory.

Recent Resources

View Other Solutions

Tissue

Canexia Health’s Find It & Fusions panels detect mutations and gene fusion events in solid tumor tissue. Tissue profiling can be used to help inform treatment decisions or predict progression of cancer based on somatic mutations found in the tumor.

Learn About Tissue Assays

Canexia Health Insights Platform

Each comprehensive report includes detailed results as well as therapeutic recommendations and expertly curated clinical trials. Our insights can help you make more informed treatment decisions.

Learn About Our Reports

Comprehensive Reports, Right From Your Lab

Perform cancer genomic profiling, right from your laboratory. From mutation identification to auto-generated clinical reports, Canexia Health’s proprietary platform puts the control back in your hands.

Learn More

Canadian Access to Follow It

Through an initiative called Project ACTT, Canexia Health is providing access to Follow It, our blood-based circulating tumor DNA (ctDNA) next-generation sequencing (NGS) hotspot panel. Project ACTT is currently open to patients throughout Canada via oncologist referral.

Learn more